

Appendix to slide43-49: The number of patients in each group and crude survival probabilities at 1, 5, and 10 years after transplantation.
(First transplants between 1991 and 2023)

Slide43. Survival after Autologous and Allogeneic HCTs				
	Years after the first transplantation	N	OS	95% C.I.
Auto	At transplantation	42,698		
	1 year	32,812	84.9%	84.6 - 85.3%
	5 years	16,294	64.0%	63.5 - 64.5%
	10 years	6,591	52.4%	51.8 - 53.0%
Allo	At transplantation	72,132		
	1 year	44,205	65.6%	65.2 - 65.9%
	5 years	23,491	49.6%	49.2 - 50.0%
	10 years	11,585	44.9%	44.5 - 45.3%

Slide44. Survival after Allogeneic HCTs, by Donor Type and Graft Source				
	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	12,641		
	1 year	9,111	74.1%	73.3 - 74.9%
	5 years	6,067	59.0%	58.1 - 59.8%
	10 years	3,852	55.0%	54.1 - 55.9%
Rel-PB	At transplantation	15,240		
	1 year	8,755	62.4%	61.6 - 63.2%
	5 years	3,801	43.4%	42.6 - 44.3%
	10 years	1,652	37.8%	36.8 - 38.7%
UR-BM	At transplantation	23,999		
	1 year	15,213	67.4%	66.8 - 68.0%
	5 years	8,666	51.6%	50.9 - 52.3%
	10 years	4,181	46.6%	45.9 - 47.3%
UR-PB	At transplantation	1,823		
	1 year	1,081	72.5%	70.3 - 74.6%
	5 years	266	55.0%	52.2 - 57.6%
	10 years	12	45.4%	40.6 - 50.0%
UR-CB	At transplantation	18,429		
	1 year	10,045	59.2%	58.4 - 59.9%
	5 years	4,691	44.7%	43.9 - 45.5%
	10 years	1,888	40.3%	39.4 - 41.1%

Slide45. Survival after HCTs for Leukemia				
	Years after the first transplantation	N	OS	95% C.I.
AML	At transplantation	28,277		
	1 year	17,031	64.7%	64.2 - 65.3%
	5 years	8,533	46.8%	46.2 - 47.4%
	10 years	3,991	42.1%	41.4 - 42.7%
ALL	At transplantation	14,419		
	1 year	9,824	72.2%	71.5 - 73.0%
	5 years	5,270	53.5%	52.6 - 54.3%
	10 years	2,712	49.0%	48.1 - 49.9%
ATL	At transplantation	3,134		
	1 year	1,397	47.7%	45.9 - 49.4%
	5 years	630	31.8%	30.1 - 33.6%
	10 years	250	26.3%	24.5 - 28.2%
CML	At transplantation	3,935		
	1 year	2,711	71.9%	70.4 - 73.2%
	5 years	1,890	59.9%	58.3 - 61.4%
	10 years	1,196	55.7%	54.0 - 57.3%
MDS	At transplantation	8,041		
	1 year	4,908	66.0%	64.9 - 67.0%
	5 years	2,354	48.9%	47.7 - 50.0%
	10 years	979	42.0%	40.7 - 43.3%

Slide46. Survival after HCTs for Malignant Lymphoma and MM/PCD				
	Years after the first transplantation	N	OS	95% C.I.
NHL	At transplantation	25,996		
	1 year	17,129	72.4%	71.8 - 72.9%
	5 years	8,998	57.0%	56.3 - 57.6%
	10 years	3,836	49.4%	48.6 - 50.1%
HL	At transplantation	1,897		
	1 year	1,501	87.7%	86.1 - 89.1%
	5 years	784	71.7%	69.3 - 73.9%
	10 years	295	64.0%	61.2 - 66.6%
Other lymphoma / type missing	At transplantation	628		
	1 year	385	71.1%	67.2 - 74.6%
	5 years	203	54.4%	49.9 - 58.6%
	10 years	122	46.4%	41.7 - 51.0%
MM/PCD	At transplantation	14,629		
	1 year	11,907	91.6%	91.2 - 92.1%
	5 years	5,209	66.4%	65.5 - 67.3%
	10 years	1,456	45.0%	43.8 - 46.2%

Slide47. Survival after Autologous HCTs for Acute Leukemia by Recipient Age				
	Years after the first transplantation	N	OS	95% C.I.
AML : Age ≤ 15	At transplantation	237		
	1 year	204	86.9%	81.9 - 90.6%
	5 years	147	64.3%	57.8 - 70.1%
	10 years	111	61.6%	55.0 - 67.5%
AML : Age ≥ 16	At transplantation	1,567		
	1 year	1,231	84.0%	82.0 - 85.7%
	5 years	765	68.4%	65.9 - 70.7%
	10 years	389	64.9%	62.2 - 67.4%
ALL : Age ≤ 15	At transplantation	393		
	1 year	320	81.4%	77.2 - 84.9%
	5 years	230	59.7%	54.6 - 64.3%
	10 years	155	55.4%	50.3 - 60.2%
ALL : Age ≥ 16	At transplantation	351		
	1 year	212	61.6%	56.2 - 66.4%
	5 years	97	31.7%	26.8 - 36.7%
	10 years	55	27.0%	22.2 - 32.0%

Slide48. Survival after Autologous HCTs for Malignant Lymphoma by Recipient Age				
	Years after the first transplantation	N	OS	95% C.I.
NHL : Age ≤ 15	At transplantation	226		
	1 year	176	78.6%	72.7 - 83.5%
	5 years	142	71.4%	65.0 - 76.8%
	10 years	101	70.7%	64.2 - 76.3%
NHL : Age ≥ 16	At transplantation	18,070		
	1 year	13,020	80.0%	79.4 - 80.6%
	5 years	6,678	63.1%	62.3 - 63.9%
	10 years	2,705	53.8%	52.9 - 54.7%
HL : Age ≤ 15	At transplantation	39		
	1 year	34	87.2%	71.9 - 94.5%
	5 years	16	76.1%	59.0 - 86.8%
	10 years	9	76.1%	59.0 - 86.8%
HL : Age ≥ 16	At transplantation	1,682		
	1 year	1,356	90.2%	88.7 - 91.6%
	5 years	715	74.4%	71.9 - 76.6%
	10 years	262	66.6%	63.6 - 69.4%

Slide49. Survival after Autologous HCTs for MM / PCD, Recipient Age ≥16				
	Years after the first transplantation	N	OS	95% C.I.
	At transplantation	13,639		
	1 year	11,360	94.2%	93.7 - 94.6%
	5 years	4,985	69.1%	68.1 - 70.0%
	10 years	1,341	46.5%	45.1 - 47.7%

Appendix to slide50-96: The number of patients in each group and crude survival probabilities at 1, 5 years after transplantation.
 (Survival after first HCTs between 2014 and 2023)

Slide50. Survival after Allogeneic HCTs for AML by Donor Type and Graft Source, Recipient Age ≤15				
	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	155		
	1 year	112	77.7%	70.2 - 83.5%
	5 years	54	64.1%	55.5 - 71.4%
Rel-PB	At transplantation	104		
	1 year	72	75.4%	65.8 - 82.7%
	5 years	25	52.1%	41.3 - 61.9%
UR-BM	At transplantation	137		
	1 year	98	79.8%	71.8 - 85.8%
	5 years	37	64.4%	54.9 - 72.3%
UR-CB	At transplantation	284		
	1 year	211	82.5%	77.4 - 86.6%
	5 years	72	59.8%	52.9 - 65.9%

Slide52. Survival after HLA-identical Sibling donor HCTs for AML by Disease Status, Recipient Age ≤15				
	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	61		
	1 year	55	96.7%	87.4 - 99.2%
	5 years	22	80.8%	67.1 - 89.2%
Advanced risk	At transplantation	31		
	1 year	17	54.8%	36.0 - 70.3%
	5 years	8	45.2%	27.4 - 61.4%

Slide55. Survival after UR-BMT for AML by Disease Status, Recipient Age ≥16				
	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	2,067		
	1 year	1,421	79.1%	77.3 - 80.9%
	5 years	568	61.0%	58.6 - 63.4%
Advanced risk	At transplantation	897		
	1 year	341	42.4%	39.0 - 45.7%
	5 years	115	26.0%	22.9 - 29.2%

Slide51. Survival after Allogeneic HCTs for AML by Donor Type and Graft Source, Recipient Age ≥16				
	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	501		
	1 year	349	75.4%	71.3 - 79.0%
	5 years	143	57.2%	52.3 - 61.7%
Rel-PB	At transplantation	3,016		
	1 year	1,773	67.7%	65.9 - 69.3%
	5 years	507	47.0%	45.0 - 49.1%
UR-BM	At transplantation	2,971		
	1 year	1,765	67.9%	66.2 - 69.6%
	5 years	683	50.2%	48.2 - 52.2%
UR-CB	At transplantation	4,477		
	1 year	2,489	62.3%	60.9 - 63.8%
	5 years	760	45.8%	44.2 - 47.5%

Slide53. Survival after HLA-identical Sibling donor HCTs for AML by Disease Status, Recipient Age ≥16				
	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	1,192		
	1 year	913	84.6%	82.4 - 86.5%
	5 years	316	64.0%	60.8 - 67.0%
Advanced risk	At transplantation	555		
	1 year	250	50.0%	45.7 - 54.2%
	5 years	87	31.1%	27.0 - 35.3%

Slide56. Survival after UR-CBT for AML by Disease Status, Recipient Age ≤15				
	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	189		
	1 year	163	95.6%	91.4 - 97.8%
	5 years	58	75.2%	66.9 - 81.6%
Advanced risk	At transplantation	95		
	1 year	48	56.4%	45.5 - 66.0%
	5 years	14	29.4%	19.6 - 39.9%

Slide54. Survival after UR-BMT for AML by Disease Status, Recipient Age ≤15				
	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	95		
	1 year	77	93.2%	85.4 - 96.9%
	5 years	31	77.2%	66.1 - 85.0%
Advanced risk	At transplantation	42		
	1 year	21	52.0%	36.0 - 65.8%
	5 years	6	37.1%	22.0 - 52.3%

Slide57. Survival after UR-CBT for AML by Disease Status, Recipient Age ≥16				
	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	2,291		
	1 year	1,555	76.6%	74.8 - 78.3%
	5 years	493	61.7%	59.4 - 63.9%
Advanced risk	At transplantation	2,184		
	1 year	933	47.4%	45.3 - 49.5%
	5 years	266	29.5%	27.4 - 31.7%

**Slide58. Survival after Allogeneic HCTs for ALL
by Donor Type and Graft Source, Recipient Age ≤15**

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	195		
	1 year	153	85.3%	79.4 - 89.6%
	5 years	59	68.9%	60.9 - 75.6%
Rel-PB	At transplantation	107		
	1 year	56	57.3%	47.3 - 66.1%
	5 years	17	41.7%	31.7 - 51.3%
UR-BM	At transplantation	206		
	1 year	165	87.6%	82.1 - 91.4%
	5 years	64	71.8%	64.2 - 78.1%
UR-CB	At transplantation	351		
	1 year	257	86.6%	82.4 - 89.8%
	5 years	120	76.1%	70.7 - 80.6%

**Slide60. Survival after HLA-identical Sibling donor HCTs for ALL
by Disease risk status, Recipient Age ≤15**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	55		
	1 year	48	94.4%	83.6 - 98.2%
	5 years	23	85.4%	71.5 - 92.8%
Advanced risk	At transplantation	62		
	1 year	44	78.2%	65.5 - 86.8%
	5 years	13	54.8%	39.7 - 67.6%

**Slide63. Survival after UR-BMT for ALL
by Disease Status, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	1,140		
	1 year	880	85.5%	83.3 - 87.5%
	5 years	362	68.8%	65.6 - 71.7%
Advanced risk	At transplantation	318		
	1 year	176	64.5%	58.8 - 69.7%
	5 years	52	41.0%	34.7 - 47.1%

**Slide59. Survival after Allogeneic HCTs for ALL
by Donor Type and Graft Source, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	284		
	1 year	226	86.6%	82.0 - 90.1%
	5 years	100	69.7%	63.4 - 75.2%
Rel-PB	At transplantation	1,166		
	1 year	815	79.0%	76.5 - 81.3%
	5 years	243	60.3%	57.0 - 63.5%
UR-BM	At transplantation	1,458		
	1 year	1,056	81.0%	78.8 - 82.9%
	5 years	414	62.8%	60.0 - 65.6%
UR-CB	At transplantation	1,278		
	1 year	860	75.2%	72.7 - 77.6%
	5 years	272	59.9%	56.8 - 62.8%

**Slide61. Survival after HLA-identical Sibling donor HCTs for ALL
by Disease Status, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	639		
	1 year	534	91.5%	89.0 - 93.5%
	5 years	224	75.0%	71.0 - 78.6%
Advanced risk	At transplantation	173		
	1 year	107	68.0%	60.4 - 74.5%
	5 years	28	40.7%	32.1 - 49.1%

**Slide64. Survival after UR-CBT for ALL
by Disease Status, Recipient Age ≤15**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	160		
	1 year	124	91.8%	86.0 - 95.3%
	5 years	63	83.1%	75.3 - 88.6%
Advanced risk	At transplantation	191		
	1 year	133	82.2%	75.8 - 87.0%
	5 years	57	70.4%	62.7 - 76.8%

**Slide62. Survival after UR-BMT for ALL
by Disease Status, Recipient Age ≤15**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	103		
	1 year	90	94.0%	87.0 - 97.2%
	5 years	38	83.1%	73.2 - 89.6%
Advanced risk	At transplantation	103		
	1 year	75	81.1%	72.0 - 87.5%
	5 years	26	59.8%	47.8 - 69.9%

**Slide65. Survival after UR-CBT for ALL
by Disease Status, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	838		
	1 year	632	83.8%	81.1 - 86.2%
	5 years	218	72.1%	68.6 - 75.3%
Advanced risk	At transplantation	439		
	1 year	227	58.7%	53.8 - 63.2%
	5 years	53	35.5%	30.3 - 40.7%

Slide66. Survival after Allogeneic HCTs for CML
by Donor Type and Graft Source, Recipient Age ≤15

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM / Rel-PB	At transplantation	14		
	1 year	9	76.2%	42.7 - 91.7%
	5 years	8	76.2%	42.7 - 91.7%
UR-BM	At transplantation	15		
	1 year	10	78.8%	47.3 - 92.7%
	5 years	6	70.9%	39.5 - 88.1%
UR-CB	At transplantation	7		
	1 year	7	100.0%	
	5 years	4	100.0%	

Slide67. Survival after Allogeneic HCTs for CML
by Donor Type and Graft Source, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	28		
	1 year	24	96.0%	74.8 - 99.4%
	5 years	10	86.3%	62.4 - 95.5%
Rel-PB	At transplantation	179		
	1 year	132	82.4%	75.7 - 87.3%
	5 years	39	64.8%	56.0 - 72.2%
UR-BM	At transplantation	218		
	1 year	153	82.4%	76.4 - 87.0%
	5 years	65	69.7%	62.2 - 76.0%
UR-CB	At transplantation	187		
	1 year	122	73.9%	66.8 - 79.7%
	5 years	59	68.1%	60.4 - 74.6%

Slide68. Survival after HLA-identical Sibling donor HCTs for CML
by Disease Status, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	50		
	1 year	43	97.8%	85.3 - 99.7%
	5 years	14	87.1%	67.4 - 95.3%
Advanced risk	At transplantation	72		
	1 year	57	85.5%	74.6 - 91.9%
	5 years	20	63.5%	50.1 - 74.2%

Slide69. Survival after UR-BMT for CML
by Disease Status, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	95		
	1 year	63	83.7%	73.9 - 90.0%
	5 years	22	75.9%	64.5 - 84.1%
Advanced risk	At transplantation	123		
	1 year	90	81.4%	73.2 - 87.4%
	5 years	43	65.5%	55.3 - 73.9%

Slide70. Survival after UR-CBT for CML
by Disease Status, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	59		
	1 year	45	86.0%	73.9 - 92.7%
	5 years	12	81.6%	68.3 - 89.7%
Advanced risk	At transplantation	128		
	1 year	77	68.3%	59.2 - 75.8%
	5 years	47	62.2%	52.7 - 70.4%

Slide71. Survival after Allogeneic HCTs for MDS
by Donor Type and Graft Source, Recipient Age ≤15

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	61		
	1 year	55	95.1%	85.4 - 98.4%
	5 years	28	91.3%	80.2 - 96.3%
Rel-PB	At transplantation	15		
	1 year	11	85.7%	53.9 - 96.2%
	5 years	4	77.1%	44.2 - 92.1%
UR-BM	At transplantation	118		
	1 year	92	92.8%	86.0 - 96.3%
	5 years	39	82.0%	72.4 - 88.6%
UR-CB	At transplantation	41		
	1 year	29	88.9%	72.9 - 95.7%
	5 years	14	82.8%	65.5 - 91.9%

Slide72. Survival after Allogeneic HCTs for MDS
by Donor Type and Graft Source, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	181		
	1 year	119	70.1%	62.7 - 76.2%
	5 years	45	47.5%	39.4 - 55.2%
Rel-PB	At transplantation	899		
	1 year	516	65.9%	62.6 - 68.9%
	5 years	138	46.9%	43.1 - 50.6%
UR-BM	At transplantation	1,478		
	1 year	908	68.2%	65.7 - 70.5%
	5 years	277	46.7%	43.8 - 49.6%
UR-CB	At transplantation	1,238		
	1 year	670	61.6%	58.7 - 64.3%
	5 years	195	44.6%	41.4 - 47.8%

**Slide73. Survival after HLA-identical Sibling donor HCTs for MDS
by Disease Status, Recipient Age ≤15**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	34		
	1 year	31	94.0%	78.2 - 98.5%
	5 years	17	94.0%	78.2 - 98.5%
Advanced risk	At transplantation	7		
	1 year	7	100.0%	
	5 years	5	71.4%	25.8 - 92.0%

**Slide76. Survival after UR-BMT for MDS
by Disease Status, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	514		
	1 year	334	71.5%	67.3 - 75.3%
	5 years	112	51.3%	46.3 - 56.0%
Advanced risk	At transplantation	913		
	1 year	539	65.9%	62.7 - 69.0%
	5 years	158	43.8%	40.1 - 47.4%

**Slide79. Survival after Allogeneic HCTs for NHL
by Donor Type and Graft Source, Recipient Age ≤15**

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	24		
	1 year	17	77.9%	54.7 - 90.2%
	5 years	8	73.1%	49.4 - 86.9%
Rel-PB	At transplantation	22		
	1 year	11	53.3%	30.6 - 71.6%
	5 years	4	42.4%	21.1 - 62.4%
UR-BM	At transplantation	30		
	1 year	21	76.5%	57.0 - 88.1%
	5 years	7	67.5%	46.1 - 81.9%
UR-CB	At transplantation	41		
	1 year	28	74.7%	58.0 - 85.5%
	5 years	14	70.8%	53.0 - 82.9%

**Slide74. Survival after HLA-identical Sibling donor HCTs for MDS
by Disease Status, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	175		
	1 year	121	75.3%	68.1 - 81.1%
	5 years	52	61.4%	53.2 - 68.5%
Advanced risk	At transplantation	320		
	1 year	196	68.8%	63.3 - 73.7%
	5 years	66	47.7%	41.4 - 53.7%

**Slide77. Survival after UR-CBT for MDS
by Disease Status, Recipient Age ≤15**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	14		
	1 year	9	83.1%	47.2 - 95.5%
	5 years	6	83.1%	47.2 - 95.5%
Advanced risk	At transplantation	21		
	1 year	15	89.1%	62.7 - 97.2%
	5 years	7	77.2%	49.9 - 90.8%

**Slide80. Survival after Allogeneic HCTs for NHL
by Donor Type and Graft Source, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	128		
	1 year	71	64.4%	55.3 - 72.2%
	5 years	30	53.0%	43.2 - 61.8%
Rel-PB	At transplantation	1,081		
	1 year	540	55.5%	52.4 - 58.4%
	5 years	148	40.7%	37.4 - 43.9%
UR-BM	At transplantation	672		
	1 year	398	64.2%	60.4 - 67.8%
	5 years	185	50.9%	46.8 - 54.8%
UR-CB	At transplantation	1,140		
	1 year	525	51.7%	48.7 - 54.7%
	5 years	205	40.8%	37.7 - 43.8%

**Slide75. Survival after UR-BMT for MDS
by Disease Status, Recipient Age ≤15**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	74		
	1 year	66	97.2%	89.2 - 99.3%
	5 years	36	90.2%	79.3 - 95.6%
Advanced risk	At transplantation	30		
	1 year	20	89.6%	71.2 - 96.5%
	5 years	3	69.4%	45.4 - 84.4%

**Slide78. Survival after UR-CBT for MDS
by Disease Status, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	370		
	1 year	213	66.5%	61.3 - 71.2%
	5 years	59	50.3%	44.5 - 55.9%
Advanced risk	At transplantation	838		
	1 year	445	59.5%	56.1 - 62.8%
	5 years	135	42.1%	38.2 - 45.9%

**Slide81. Survival after HLA-identical Sibling donor HCTs for NHL
by Disease Status, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
CR	At transplantation	178		
	1 year	143	85.6%	79.4 - 90.0%
	5 years	52	71.6%	63.6 - 78.1%
PR	At transplantation	113		
	1 year	78	73.0%	63.7 - 80.3%
	5 years	29	57.3%	46.9 - 66.5%
NIR	At transplantation	248		
	1 year	102	44.7%	38.4 - 50.9%
	5 years	36	31.2%	25.1 - 37.4%

**Slide84. Survival after UR-CBT for NHL
by Disease Status, Recipient Age ≤15**

	Years after the first transplantation	N	OS	95% C.I.
CR / PR	At transplantation	26		
	1 year	21	84.1%	63.1 - 93.7%
	5 years	11	77.7%	53.2 - 90.4%
NIR	At transplantation	15		
	1 year	7	57.3%	28.1 - 78.3%
	5 years	3	57.3%	28.1 - 78.3%

**Slide82. Survival after UR-BMT for NHL
by Disease Status, Recipient Age ≤15**

	Years after the first transplantation	N	OS	95% C.I.
CR / PR	At transplantation	16		
	1 year	10	68.2%	39.5 - 85.4%
	5 years	2	60.6%	32.1 - 80.2%
NIR	At transplantation	14		
	1 year	11	85.7%	53.9 - 96.2%
	5 years	5	76.2%	42.1 - 91.8%

**Slide85. Survival after UR-CBT for NHL
by Disease Status, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
1CR	At transplantation	159		
	1 year	98	70.3%	62.5 - 76.9%
	5 years	37	58.2%	49.5 - 65.9%
2CR	At transplantation	123		
	1 year	68	64.6%	55.3 - 72.5%
	5 years	32	60.3%	50.7 - 68.7%
>=3CR	At transplantation	54		
	1 year	36	72.9%	58.6 - 83.0%
	5 years	16	58.3%	42.7 - 71.1%
1PR	At transplantation	121		
	1 year	62	56.8%	47.3 - 65.2%
	5 years	19	47.0%	37.5 - 55.9%
2PR	At transplantation	125		
	1 year	55	51.2%	41.8 - 59.8%
	5 years	28	41.9%	32.6 - 50.9%
NIR	At transplantation	557		
	1 year	205	40.5%	36.3 - 44.6%
	5 years	73	28.5%	24.6 - 32.6%

**Slide83. Survival after UR-BMT for NHL
by Disease Status, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
CR	At transplantation	298		
	1 year	210	75.7%	70.4 - 80.2%
	5 years	107	60.3%	54.2 - 65.9%
PR	At transplantation	148		
	1 year	85	65.1%	56.7 - 72.3%
	5 years	33	51.1%	42.1 - 59.4%
NIR	At transplantation	226		
	1 year	103	48.4%	41.7 - 54.8%
	5 years	45	38.2%	31.6 - 44.8%

Slide86. Survival after Autologous HCTs for MM / PCD, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
	At transplantation	8,025		
	1 year	6,457	95.8%	95.3 - 96.2%
	5 years	2,207	77.6%	76.4 - 78.8%

Slide87. Survival after Allogeneic HCTs for MM / PCD by Donor Type and Graft Source, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM / Rel-PB	At transplantation	95		
	1 year	47	57.7%	46.9 - 67.1%
	5 years	12	33.9%	23.6 - 44.5%
UR-BM	At transplantation	113		
	1 year	66	61.3%	51.6 - 69.7%
	5 years	21	42.2%	32.0 - 52.0%
UR-CB	At transplantation	77		
	1 year	32	42.5%	31.3 - 53.2%
	5 years	5	15.3%	7.5 - 25.8%

Slide88. Survival after Autologous HCTs for MM / PCD by Disease Status, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
CR (including sCR)	At transplantation	1,923		
	1 year	1,550	97.9%	97.1 - 98.5%
	5 years	456	81.9%	79.3 - 84.2%
VGPR	At transplantation	2,614		
	1 year	2,078	96.9%	96.1 - 97.5%
	5 years	664	78.1%	75.9 - 80.2%
PR	At transplantation	2,477		
	1 year	2,044	95.4%	94.4 - 96.1%
	5 years	800	74.9%	72.7 - 77.0%
SD	At transplantation	180		
	1 year	152	91.9%	86.7 - 95.1%
	5 years	58	64.8%	56.3 - 72.1%
PD / Rel	At transplantation	150		
	1 year	74	64.4%	55.7 - 71.8%
	5 years	20	36.0%	26.7 - 45.3%

Slide89. Survival after Allogeneic HCTs for MM / PCD by Disease Status, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
CR (including sCR) / VGPR / PR	At transplantation	216		
	1 year	129	66.2%	59.3 - 72.2%
	5 years	33	39.4%	31.7 - 46.9%
SD / PD / Rel	At transplantation	83		
	1 year	22	29.2%	19.8 - 39.3%
	5 years	4	13.1%	6.5 - 22.1%

Slide90. Survival after HLA-identical Sibling donor HCTs for MM / PCD by Disease Status, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
CR (including sCR) / VGPR / PR	At transplantation	38		
	1 year	27	80.8%	63.8 - 90.4%
	5 years	9	51.0%	32.3 - 66.9%
SD / PD / Rel	At transplantation	14		
	1 year	4	28.6%	8.8 - 52.4%
	5 years	1	21.4%	5.2 - 44.8%

Slide91. Survival after UR-BMT for MM / PCD by Disease Status, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
CR (including sCR) / VGPR / PR	At transplantation	83		
	1 year	57	71.8%	60.6 - 80.3%
	5 years	17	49.8%	37.0 - 61.4%
SD / PD / Rel	At transplantation	27		
	1 year	8	32.9%	16.3 - 50.6%
	5 years	3	19.2%	6.6 - 36.8%

Slide92. Survival after UR-CBT for MM / PCD by Disease Status, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
CR (including sCR) / VGPR / PR	At transplantation	44		
	1 year	24	56.6%	40.7 - 69.7%
	5 years	5	22.8%	10.6 - 37.8%
SD / PD / Rel	At transplantation	32		
	1 year	8	25.0%	11.8 - 40.7%
	5 years	0		

**Slide93. Survival after Allogeneic HCTs for AA
by Donor Type and Graft Source, Recipient Age ≤15**

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	117		
	1 year	104	97.3%	91.9 - 99.1%
	5 years	34	96.4%	90.6 - 98.6%
Rel-PB	At transplantation	9		
	1 year	5	88.9%	43.3 - 98.4%
	5 years	2	88.9%	43.3 - 98.4%
UR-BM	At transplantation	134		
	1 year	107	96.0%	90.8 - 98.3%
	5 years	46	94.1%	88.0 - 97.2%
UR-CB	At transplantation	31		
	1 year	28	100.0%	
	5 years	8	100.0%	

**Slide95. Survival after Allogeneic HCTs for AA
by Donor Type and Graft Source, Recipient Age ≤15**

	Years after the first transplantation	N	OS	95% C.I.
HLA-identical Sibling	At transplantation	86		
	1 year	75	97.6%	90.6 - 99.4%
	5 years	24	97.6%	90.6 - 99.4%
UR-BM	At transplantation	134		
	1 year	107	96.0%	90.8 - 98.3%
	5 years	46	94.1%	88.0 - 97.2%
UR-CB	At transplantation	31		
	1 year	28	100.0%	
	5 years	8	100.0%	

**Slide94. Survival after Allogeneic HCTs for AA
by Donor Type and Graft Source, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	181		
	1 year	152	93.7%	89.0 - 96.5%
	5 years	64	88.5%	82.2 - 92.7%
Rel-PB	At transplantation	96		
	1 year	66	79.8%	70.2 - 86.6%
	5 years	21	73.1%	61.6 - 81.7%
UR-BM	At transplantation	218		
	1 year	161	82.1%	76.2 - 86.7%
	5 years	81	75.4%	68.6 - 80.9%
UR-CB	At transplantation	116		
	1 year	75	73.1%	64.0 - 80.3%
	5 years	34	70.9%	61.6 - 78.4%

**Slide96. Survival after Allogeneic HCTs for AA
by Donor Type and Graft Source, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
HLA-identical Sibling	At transplantation	176		
	1 year	148	91.9%	86.7 - 95.1%
	5 years	66	86.7%	80.1 - 91.1%
UR-BM	At transplantation	218		
	1 year	161	82.1%	76.2 - 86.7%
	5 years	81	75.4%	68.6 - 80.9%
UR-CB	At transplantation	116		
	1 year	75	73.1%	64.0 - 80.3%
	5 years	34	70.9%	61.6 - 78.4%